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OBJECTIVES We sought to assess mortality and morbidity in pregnant women with hypertrophic
cardiomyopathy (HCM).
BACKGROUND The risk associated with pregnancy in women with HCM is an important and increasingly
frequent clinical issue for which systematic data are not available and a large measure of
uncertainty persists.
METHODS Maternal mortality in 91 consecutively evaluated families with HCM was compared with that
reported in the general population. The study cohort included 100 women with HCM with
one or more live births, for a total of 199 live births. Morbidity related to HCM during
pregnancy was investigated in 40 women evaluated within five years of their pregnancy.
RESULTS Two pregnancy-related deaths occurred, both in patients at a particularly high risk. The
maternal mortality rate was 10 per 1,000 live births (95% confidence interval [CI] 1.1 to
36.2/1,000) and was in excess of the expected mortality in the general Italian population
(relative risk 17.1, 95% CI 2.0 to 61.8). In the 40 patients evaluated within close proximity
of their pregnancy, 1 (4%) of the 28 who were previously asymptomatic and 5 (42%) of the
12 with symptoms progressed to functional class III or IV during pregnancy (p  0.01). One
patient had atrial fibrillation and one had syncope, both of whom had already experienced
similar and recurrent events before their pregnancy.
CONCLUSIONS Maternal mortality is increased in patients with HCM compared with the general population.
However, absolute maternal mortality is low and appears to be principally confined to women
at a particularly high risk. In the presence of a favorable clinical profile, the progression of
symptoms, atrial fibrillation, and syncope are also uncommon during pregnancy. (J Am Coll
Cardiol 2002;40:1864–9) © 2002 by the American College of Cardiology Foundation
In recent years, clinical and genetic screening of families
with hypertrophic cardiomyopathy (HCM), as well as a
more widespread use of echocardiography, has led to the
identification of a growing number of young women with
this disease who were previously unaware of their condition
(1–4). Many such patients may contemplate the possibility
of pregnancy. Therefore, more so than in the past, cardiol-
ogists are confronted with the difficult issue of the risk
associated with gestation and delivery in this disease. How-
ever, the few studies on the course of pregnancy in women
with HCM were performed 20 years ago in relatively
small, selected patient populations, and they reported no
deaths (5,6). In contrast, several case reports have described
severe cardiac complications and death during pregnancy
(7–13). Therefore, a large measure of uncertainty persists
regarding the risk associated with gestation and delivery in
women with HCM.
In the present study, maternal mortality was assessed in
90 families with HCM and was compared with that
reported in the general population. In addition, morbidity
related to HCM during pregnancy was investigated in a
group of patients evaluated within close proximity of their
pregnancy. Our findings offer an estimate of the risk of
death during pregnancy in HCM and characterize the
clinical profile of those patients more likely to experience
disease-related complications.
METHODS
Study population. The populations of patients with HCM
consecutively evaluated at three centers between 1984 and
2000 were combined. The patients known to have the
familial form of the disease were selected, and their pedi-
grees were reconstructed. The affected family members and
their first-degree relatives were included in the pedigrees.
The occurrence of death during pregnancy was assessed in
women with HCM. Maternal mortality in the general
Italian population was used for comparison. As modern
statistics on maternal mortality in Italy were available from
1955 (14), only women with a first pregnancy after 1954
were examined.
Because HCM is an autosomal-dominant disease, it
could be expected that a proportion of the family members
who were not evaluated were affected. Therefore, to prevent
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an underestimation of maternal mortality due to undiag-
nosed disease, the occurrence of pregnancy-related death
was also assessed in an extended cohort that included the
affected women, as well as the first-degree relatives with a
pregnancy after 1954 who had not been clinically and
echocardiographically evaluated. Maternal mortality was
defined as death either during gestation or at or shortly after
delivery.
The potential relationship between clinical features of
HCM and disease-related morbidity during pregnancy was
investigated in patients evaluated at the participating centers
either shortly before or within five years of their pregnancy.
This five-year interval was arbitrarily selected as one brief
enough to allow the patients to recall with sufficient accu-
racy the severity of their clinical limitation before preg-
nancy, as well as to justify the assumption that their
functional profile (i.e., presence or absence of left ventricular
[LV] outflow obstruction) had remained unchanged from
the time of pregnancy. Cardiac deterioration with develop-
ment of heart failure during pregnancy was defined as a
marked increase in shortness of breath and fatigue to New
York Heart Association functional class III or IV. Syncope
was defined as a sudden and brief loss of consciousness
associated with a loss of postural tone and a spontaneous
recovery (15). The potential relationship between morpho-
logic features assessed by echocardiography and the course
of pregnancy was evaluated only in those patients in whom
an echocardiogram had been obtained before pregnancy.
Echocardiographic diagnosis and evaluation. The diag-
nosis of HCM was based on the two-dimensional echocar-
diographic demonstration of a hypertrophied, nondilated
LV (wall thickness 15 mm) in the absence of another
cardiac or systemic disease capable of producing a similar
magnitude of wall thickening (1,4). In relatives of patients
with HCM, a wall thickness 13 mm was used as a
criterion for diagnosis (16). The extent and distribution of
LV hypertrophy was evaluated, and the magnitude of
hypertrophy was expressed in terms of maximal wall thick-
ness (17–19). The LV end-diastolic cavity dimension and
left atrial size were assessed by M-mode echocardiography
in a standard fashion. Left ventricular outflow obstruction
was diagnosed on the basis of the presence of prolonged
systolic contact between the mitral leaflets and interventric-
ular septum or a Doppler-estimated pressure gradient 30
mm Hg under basal conditions (4,17–19).
Statistical analysis. Results are presented as the mean
value  SD or proportions, as appropriate. Maternal mor-
tality was computed as the ratio between the number of
deaths during pregnancy and the total number of pregnan-
cies in each group. The maternal mortality observed in the
present study cohort was compared with that of the general
Italian population. Statistics on maternal mortality in Italy
were available only between 1955 and 1984. During the
1955 to 1984 period, maternal mortality decreased substan-
tially from 1.33 per 1,000 live births in 1955 to 0.11 per
1,000 live births in 1984 (14). Therefore, age- and year-
specific mortality rates were used to compare the mortality
in the study cohort with that reported in the Italian
population. Expected maternal deaths were computed by
indirect standardization (i.e., by summing age- and year-
specific expected deaths, which were calculated by multiply-
ing age- and year-specific rates for the number of pregnan-
cies in each age and year group). Relative risks were
estimated as the ratio between the number of observed and
the number of expected deaths. Ninety-five percent confi-
dence intervals (CIs) for maternal mortality and relative
risks were calculated with the assumption of an underlying
Poisson distribution for rare events. Proportions between
subgroups of patients were compared by means of the
chi-square or Fisher exact test, as appropriate. A p value
0.05 was considered as statistically significant.
RESULTS
In the three patient cohorts, a total of 91 HCM-affected
families were identified that included women with a first
pregnancy after 1954. Of these families, 32 were evaluated
at the University La Sapienza, Rome; 20 at the Ospedale
Rivoli, Turin; and 39 at the Ente Ospedaliero Ospedali
Galliera, Genoa. In these families, 100 women known to
have HCM had pregnancies after 1954; their age at first
pregnancy ranged from 15 to 37 years (mean 25). The total
number of live births was 199 (range 1 to 5, mean 2). A
family history of sudden death in a first-degree relative 50
years of age was present in 48 (48%) of the 100 women;
these 48 patients belonged to 27 (30%) of the 91 HCM-
affected families.
Of these 100 family members with HCM and pregnan-
cies after 1954, 78 were evaluated at the participating
centers. Of the remaining 22, 11 could not be directly
assessed because they had died of either HCM-related
causes (n  9) or noncardiac causes (n  2) before our first
evaluation of the proband, and 11 could not be directly
assessed because they lived in distant areas. Documentation
of diagnosis (either as an echocardiographic report or
hospital chart) was verified at our centers in 17 of the 22
patients who were not directly evaluated. The remaining five
women had died suddenly before the age of 50 years.
Of the 78 women with HCM and previous pregnancies
who were evaluated at our centers, 75 (96%) were in
functional class I or II, and 3 (4%) were in functional class
III or IV at the time of our initial evaluation. Left
ventricular outflow obstruction under basal conditions was
present in 18 (23%). On the echocardiogram, the LV
Abbreviations and Acronyms
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end-diastolic dimension was 43  6 mm; maximal LV wall
thickness was 19 4 mm; and left atrial size was 43 8 mm.
Maternal mortality. Two deaths occurred during preg-
nancy in the 100 women with HCM, both were sudden.
The maternal mortality rate was 10 per 1,000 live births
(95% CI 1.1 to 36.2/1,000) (Fig. 1). In Italy, during the
period 1955 to 1984, maternal mortality decreased substan-
tially, from 1.33 per 1,000 live births in 1955 to 0.11 per
1,000 live births in 1984 (14). Maternal mortality in the
women with HCM was in excess of the age- and year-
specific mortality rates in the general Italian population
(relative risk 17.1, 95% CI 2.0 to 61.8).
To prevent an underestimation of maternal mortality due
to undiagnosed disease, the occurrence of pregnancy-related
death was also assessed in an extended cohort that included
the affected women, as well as 96 first-degree relatives with
a pregnancy after 1954 who had not been clinically and
echocardiographically evaluated. In these 96 first-degree
relatives, age at first pregnancy ranged from 16 to 43 years
(mean 24). The total number of live births was 202 (range
1 to 7, mean 2). There were no maternal deaths in these
first-degree relatives. Maternal mortality in the overall
cohort, including the 100 women with HCM and the 96
first-degree relatives not assessed for HCM, was 5 per 1,000
live births (95% CI 0.6 to 18.0/1,000) and was in excess of
the age- and year-specific mortality rates in the general
Italian population (relative risk 8.3, 95% CI 1.01 to 32.2)
(Table 1).
Clinical profile of women who died during their preg-
nancy. Both of the patients who died during pregnancy
were known to be affected; both had been judged to be at a
particularly high risk and had been strongly advised against
becoming pregnant. One of these two women had massive
LV hypertrophy with a maximal wall thickness of 30 mm
and LV outflow obstruction under basal conditions (outflow
gradient 115 mm Hg at cardiac catheterization). During
two previous pregnancies, this patient had experienced
clinical deterioration with progression to functional class
III. In 1987, during her last pregnancy, at age 39 years, the
patient deteriorated to class IV. At the time, Doppler
echocardiography confirmed the presence of LV outflow
obstruction under basal conditions, and treatment included
beta-blocking agents and diuretics. Four days after delivery,
while at home, the patient complained of palpitations,
collapsed, and died suddenly a few minutes after the onset of
symptoms. Relatives witnessed the event.
The second patient had a particularly malignant family
history of death due to HCM, with a total of eight deaths
in young relatives: five were sudden and three were due to
congestive heart failure. The morphologic and functional
presentation of the disease in five members of her family
evaluated at our centers had shown mild LV hypertrophy
(14 to 18 mm), with evolution to end-stage disease and
systolic dysfunction in three members. In 1990, at age 26
years, the patient became pregnant. At the time, she was in
functional class II. The patient was considered at high risk
because of her family history of multiple cardiac deaths and
was carefully clinically monitored throughout pregnancy. At
labor, epidural analgesia was performed during continuous
cardiovascular monitoring. Six hours after the beginning of
labor, the patient developed prolonged and recurrent runs of
ventricular tachycardia associated with a marked decrease in
systemic arterial blood pressure. Flecainide was adminis-
tered intravenously. During infusion of the drug, the patient
developed marked bradycardia with broad electrocardio-
graphic ventricular complexes. Cardiopulmonary resuscita-
tion was immediately started and, in consideration of the
critical clinical condition of the patient, a classic cesarean
section was performed. The child was born alive and well,
although the mother died despite prolonged resuscitation
attempts.
Morbidity related to HCM during pregnancy. Morbidity
related to HCM during pregnancy was assessed in 40
patients who were evaluated at the participating centers
either shortly before or within five years of their pregnancy.
Figure 1. Maternal mortality (i.e., the number of maternal deaths divided
by the total number of pregnancies) in 100 women with hypertrophic
cardiomyopathy (HCM).
Table 1. Observed and Expected Maternal Mortality in the Study Women With a First Pregnancy After 1954, and Relative Risk










Women with HCM 100 199 2 0.12 17.1 (2.0–61.8)
Women with HCM and first-degree
relatives without assessment for HCM
196 401 2 0.24 8.3 (1.01–32.2)
CI  confidence interval; HCM  hypertrophic cardiomyopathy.
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The patient cohort included 28 of the 100 women with
familial HCM and 12 additional women with sporadic
HCM. Their clinical features are reported in Table 2.
Hypertrophic cardiomyopathy was diagnosed before preg-
nancy, at age 22 6 years, in 19 of the 40 patients, and after
pregnancy, at age 31  7 years, in the remaining 21
patients. A cesarean section was performed in 13 (68%) of
the 19 patients diagnosed before pregnancy and in 2 (10%)
of the 21 diagnosed after pregnancy (p 0.05). Of these 15
cesarean sections, 11 were managed with general anesthesia
and 4 with epidural anesthesia.
During pregnancy, 6 (15%) of these 40 patients experi-
enced worsening of cardiac symptoms, with a substantial
increase in shortness of breath and fatigue. Of these six
patients, two progressed to class IV with pulmonary rales
and orthopnea, and four developed shortness of breath on
minimal effort, without signs of pulmonary congestion. In
proximity of their delivery, each of these six patients was
hospitalized in centers with a department of cardiology, and
four were managed with a cesarean section. Worsening of
their clinical condition was significantly associated with
their functional class before pregnancy, occurring in only 1
(4%) of the 28 previously asymptomatic patients and in 5
(42%) of the 12 patients with symptoms (p  0.01). With
regard to the impact of LV outflow obstruction, clinical
deterioration occurred in 3 (25%) of the 12 patients with
obstruction and in 3 (11%) of the 28 patients without
obstruction (p 0.05). None of the 40 patients experienced
sustained ventricular arrhythmias during pregnancy. The
only patient who had episodes of paroxysmal atrial fibrilla-
tion during pregnancy also had a history of paroxysmal atrial
fibrillation before pregnancy. One patient experienced a
syncopal episode during labor. This patient was one of the
six with a history of syncope before pregnancy and was the
only one with recurrent episodes of postural syncope before
pregnancy.
The potential relationship between echocardiographic
variables and the occurrence of complications during preg-
nancy was assessed in 19 (48%) of the 40 patients in whom
an echocardiogram had been obtained before pregnancy.
The LV end-diastolic cavity dimension ranged from 35 to
51 mm (mean 43  4); the maximal LV wall thickness
ranged from 14 to 38 mm (mean 21  6); and the left atrial
size ranged from 28 to 52 mm (mean 41  6). No
significant relationship was identified between these echo-
cardiographic variables and the occurrence of complications
during pregnancy.
DISCUSSION
The published data on pregnancy in HCM are scarce and
contain some inconsistencies. The available studies were
published 20 years ago and did not document maternal
deaths (5,6). These investigations, however, were based on
a small number of patients followed at tertiary-care referral
centers and were likely to include highly selected women
who were allowed to become pregnant because of their
favorable clinical profile. In contrast, several case reports
have described major cardiac complications and death dur-
ing pregnancy, generating a certain alarm regarding the
potential risk associated with gestation and delivery (7–13).
Such reports, however, did not take into account the much
higher proportion of women with HCM who survive
pregnancy.
Complexity of the study design. The difficulties of the
design of a study on maternal mortality in HCM may
explain why such a major issue has not been addressed for
20 years. A retrospective investigation of the clinical
course of pregnancy in HCM-affected women would have
the important selection bias of excluding patients who died
during pregnancy either before they came under observation
or before their diagnosis (mean age at diagnosis in HCM is
40 years) (4,20,21). A prospective investigation would
avoid these limitations but is unrealistic and virtually im-
possible because of the low rate of cardiac events and the
need for a particularly large population of young and
pregnant patients with a disease as uncommon as HCM. In
addition, a prospective study would include the major bias of
selectively enrolling those patients judged (on the basis of
arbitrary criteria) to have a clinical profile favorable enough
to experience a pregnancy.
To overcome all of these limitations, our investigation
was conceived as a reconstruction of the frequency of
maternal mortality in consecutively evaluated families with
HCM. Despite the retrospective design, the devastating
Table 2. Clinical Features and Echocardiographic Findings in
40 Women With Hypertrophic Cardiomyopathy and a
Pregnancy Within Five Years of Evaluation
Patients (no.) 40
Age at diagnosis (years) 24  6





LVOT obstruction 12 (30%)
History of syncope 6 (15%)
During exercise 3 (7%)
At rest 2 (5%)
Postural 1 (3%)
Chronic atrial fibrillation 0
Paroxysmal atrial fibrillation 1 (3%)




Calcium antagonists 2 (5%)
Amiodarone 1 (3%)
Echocardiographic findings before pregnancy (n  19)
LVIDD (mm) 43  4
Maximal LV wall thickness (mm) 21  6
Left atrial size (mm) 41  6
Data are expressed as the mean value  SD or number (%) of patients.
LV  left ventricular; LVIDD  left ventricular internal diastolic diameter;
LVOT  left ventricular outflow tract; NYHA  New York Heart Association.
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experience of a maternal death in a first-degree relative
guaranteed the accuracy of the information on the number
of such events. Although the selection of families could have
been a source of bias, each of the three centers participating
in the study predominantly followed a community-based
and regional HCM cohort (1,18,20). Consequently, the
great majority of the HCM families consisted primarily of
relatives of probands from the metropolitan areas and
adjacent regions of the three centers. Therefore, our study
families reflect a relatively unselected cohort, free of impor-
tant tertiary-care referral bias, which offered us the oppor-
tunity to establish a credible estimate of maternal mortality
in HCM.
Maternal mortality. Two women died during pregnancy.
Both women died suddenly and were known to be affected
before pregnancy. The total mortality rate in the women
with HCM was 10 per 1,000 live births. To prevent the risk
of underestimating HCM-related maternal mortality be-
cause of undiagnosed disease at the time of pregnancy, our
analysis was extended to a larger cohort that also included
first-degree relatives who had not been evaluated for the
presence of HCM. No additional maternal deaths were
identified in this group. The mortality rates in the women
with HCM and in the extended cohort were higher than
those in the general Italian population. However, the
absolute mortality rate was low. In addition, both of the
patients who died had a particularly high-risk profile; their
high risk had been identified; and both had been strongly
advised against a pregnancy. Finally, one of the two deaths,
which occurred in the hospital 10 years ago, was triggered
by recurrent episodes of ventricular tachycardia in a patient
with a particularly malignant family history of sudden death
(five sudden deaths in close relatives) and might have been
prevented by the current management of complex arrhyth-
mias. This detailed analysis of our findings leads to the
conclusion that pregnancy is safe for most patients with
HCM. Therefore, in the overall HCM population, many
young women who have a low-risk clinical profile should be
reassured about pregnancy.
Prognostic role of a family history of sudden death.
Although a family history of sudden death is generally
considered an indicator of increased risk in HCM, previous
investigations could not document a statistically significant
relationship between this variable and the risk of sudden
death, possibly because of the relatively small number of
events in the study populations (4,19,21). Because only two
of our patients died during pregnancy (one without a family
history of sudden death and one with a particularly malig-
nant pedigree), we cannot exclude that a sudden death in a
first-degree relative is associated with an increased cardiac
risk during pregnancy. However, the high number of our
study patients with a family history of sudden death who
survived gestation and delivery suggests that such a history
is not associated with a major increase in risk.
Morbidity related to HCM during pregnancy. We also
investigated the clinical course of pregnancy, as well as the
relationship between the clinical profile and the risk of
cardiac morbidity during gestation, in 40 women with
HCM who were evaluated within (either before or after)
five years of their pregnancy. Delivery was accomplished by
a cesarean section in 40% of these patients. Of note, this
procedure was performed in70% of the women diagnosed
before pregnancy, but in only 10% of those in whom the
diagnosis of HCM was unknown at the time of pregnancy,
suggesting that the frequency of cesarean section in our
patient population may partly reflect an excess of caution by
the physician.
Clinical deterioration with the development of important
symptoms of heart failure was relatively uncommon, occur-
ring in 5% of the patients without symptoms before
pregnancy and in 15% of the overall cohort, and it was
significantly related to their functional class before preg-
nancy. This observation indicates that the HCM-affected
heart, despite marked hypertrophy, a small LV cavity, and
reduced compliance, usually tolerates well the hemodynamic
burden imposed by the volume overload associated with
pregnancy (22–24). These findings, however, also suggest
caution in the management of symptomatic patients with
HCM who are contemplating pregnancy.
Clinical deterioration was twice as common in patients
with outflow obstruction than in those without obstruction.
This difference did not reach statistical significance, possibly
because of the relatively low number of patients in the two
groups. Arrhythmias and symptoms other than heart failure
were particularly uncommon during pregnancy: sustained
ventricular arrhythmias did not occur in any of the patients;
paroxysmal atrial fibrillation occurred in one; and syncope
occurred in one. Patients in these last two categories had
also experienced similar and recurrent events before preg-
nancy.
In the subgroup of patients with an echocardiogram
obtained within five years before pregnancy, none of the
cardiac morphologic features showed a significant correla-
tion with clinical deterioration during gestation. This neg-
ative finding may be partly due to the small number of
patients in this subgroup. However, the fact that one of the
two maternal deaths in the HCM families occurred in a
patient with massive hypertrophy (30 mm), a phenotype
associated with a high long-term risk of sudden death
(19,25), suggests that such a LV morphology might have an
impact on risk during pregnancy.
Conclusions. Our results indicate that the risk of death
during pregnancy is increased in patients with HCM
compared with the general population. However, our find-
ings show that absolute maternal mortality is low and
appears to be principally confined to women who are at a
particularly high risk. Major progression of symptoms, atrial
fibrillation, and syncope are uncommon and significantly
related to the patient’s clinical condition before pregnancy.
Therefore, most young women with HCM can be reassured
about their potential risks of pregnancy.
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